C34 R91
Conditions
Interventions
Group 1: Patients who have a suspicious pulmonary nodule in their medical history are included in the study. The first arm includes the "lung carcinoma" group. These patients serve as the study group.
Sponsors
Klinik für Thoraxchirurgie, Krankenhaus Martha-Maria Halle-Dölau
Klinik für Pulmologie, Krankenhaus Martha-Maria Halle-Dölau
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with lung foci that appear suspicious for lung carcinoma and are submitted to surgical histology recovery; multiple round foci may be included; Written informed consent must be obtained
Exclusion criteria
Exclusion criteria: Patients younger than 18 years; non-consenting patients, carcinomas of other types (not lung carcinoma) that occurred less than 5 years ago, recurrences of carcinomas within the last 5 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of the study is on the one hand to validate the antibody test and on the other hand to correlate the other preoperative tests with the EarlyCDT in order to be able to make a statement about a more precise diagnosis and early detection. In addition to the CDT, PET-CT, HR-CT and anamnestic data are taken into account, which can be read in the study protocol below. Further measurement instruments are the postoperative histological confirmation of the suspected diagnosis. A CRF sheet will be used for the anamnestic survey. | — |
Secondary
| Measure | Time frame |
|---|---|
| Another long-term goal of the study is to reduce the incidence of lung carcinomas III and IV and thus also to reduce lethality. This is accompanied by the establishment of a system for prevention and early detection - i.e. screening procedures. | — |
Countries
Germany
Contacts
Public ContactMarcus Krüger
Klinik für Thoraxchirurgie, Krankenhaus Martha-Maria Halle-Dölau
Outcome results
None listed